會(huì)議背景：
醫(yī)藥及生物科技領(lǐng)域近年來(lái)蓬勃發(fā)展，國(guó)際化程度日漸提高。該領(lǐng)域的私募融資交易數(shù)量不斷攀升，2020 年度，其總?cè)谫Y金額超過(guò) 107 億美元，單筆融資規(guī)模約 4400 萬(wàn)美元，同比增長(zhǎng) 42%。我國(guó) 2020 年生物醫(yī)藥領(lǐng)域 IPO 融資總金額超 147 億美元，其中以腫瘤等領(lǐng)域創(chuàng)新藥公司投融資數(shù)額較大。由此所涉及的國(guó)際化戰(zhàn)略、投融資與并購(gòu)布局策略、盡職調(diào)查、知識(shí)產(chǎn)權(quán)保護(hù)等問(wèn)題逐漸成為焦點(diǎn)走入各界視野。
 
Background：
The fields of medicine and biotechnology have developed vigorously in
 recent  years, and the degree of internationalization is increasing day
by day. The number of private financing transactions in this field continues to rise. In 2020, the total financing amount exceeded US $10.7 billion, and the single financing scale was about US $44 million, a year-on-year increase of 42%.
China's total IPO Financing in the field of biopharmacy in 2020. The amount exceeds US $14.7 billion, of which the investment and financing amount of innovative drug companies in tumor and other fields is large. Therefore, the internationalization strategy, investment and financing,
M & A layout strategy, due diligence, intellectual property protection and other issues involved have gradually become the focus and come into the vision of all walks of life.
 
會(huì)議日期：2021年12月8號(hào)
會(huì)議地點(diǎn)：上海浦東嘉里大酒店F1，浦東新區(qū)花木路1388號(hào)
會(huì)議規(guī)模：60-70人
 
13:00-13:10 推介會(huì)歡迎辭  Opening Remarks
Intralinks
13:10-13:40 主題報(bào)告--浪潮之下：中國(guó)生物醫(yī)藥的創(chuàng)新現(xiàn)狀與未來(lái)風(fēng)向
Session 1--Under the tide: innovation status and future direction of
biomedicine in China
徐佳熹 興業(yè)證券董事總經(jīng)理，研究院副院長(zhǎng)，醫(yī)藥行業(yè)首席分析師
Dr.Jiaxi XU,Managing Director,Industrial Securities Co.,Ltd.
13:40-14:10 中國(guó)生物醫(yī)藥產(chǎn)業(yè)合作與投融資報(bào)告發(fā)布
Session 2 -- China's biomedical industry cooperation and investment
and financing report
中國(guó)醫(yī)藥工業(yè)信息中心
14:10-14:40 主題報(bào)告—“生物醫(yī)藥在中國(guó)”
-推動(dòng)醫(yī)藥研發(fā)創(chuàng)新和準(zhǔn)入方面的全球化發(fā)展
-中國(guó)如何成功地將本土制藥能力從制造技術(shù)拓展到研發(fā)創(chuàng)新，并擁有更多的海外授權(quán)項(xiàng)目
Session 3 -- Pharma in China
- Driving global progress in innovation and access
-How successfully is China expanding its pharma capabilities beyond
manufacturing into innovation and having more license-out projects？
臧敬五博士，創(chuàng)始人、董事長(zhǎng)，天境生物
Dr.Jingwu ZANG,Founder and Chairman,I-Mab Biopharma
14:40-15:00 茶歇  Coffee Break
15:00-15:30 主題報(bào)告--審而慎之：盡職調(diào)查在企業(yè) IPO 以及并購(gòu)等方向?qū)嵺`問(wèn)題
Session 4-- Practice of due diligence in corporate IPO and M & A
葉玉盛，合伙人，競(jìng)天公誠(chéng)律師事務(wù)所
Yusheng YE,Partner,Jingtian & Gongcheng LLP
15:30-16:00 主題報(bào)告—“合作研發(fā)”--一種強(qiáng)有力的關(guān)系組合，對(duì)未來(lái)的醫(yī)藥研發(fā)至關(guān)重要
Session 5 -- How Collaboration-A Powerful Relationship Combination Are Essential to the Future of Pharmacy R&D
張連山 博士，全球研發(fā)總裁，江蘇恒瑞醫(yī)藥股份有限公司
Dr.Lianshan ZHANG,President of Global R&D，Hengrui Pharmaceuticals
16:00-16:30 主題報(bào)告：從投資和融資的角度來(lái)看，生物制藥市場(chǎng)是否仍將“炙手可熱”？
Session 6 -- Will the biopharma market remain “hot” from an investment and funding perspective?
尹正，三一創(chuàng)新，創(chuàng)始合伙人
Dr. Jack YIN,Partner,TIF
16:30-17:00 License out的趨勢(shì)和策略
Trend and strategy of License out
富天，昂闊醫(yī)藥首席商務(wù)官、聯(lián)合創(chuàng)始人，昂闊醫(yī)藥
Andy Fu, PharmD, MBA,Co-Founder, Chief Business Officer,OnCusp Therapeutics 
17:00-17:45 圓桌討論—策略談：2021 中國(guó)生物醫(yī)藥與健康創(chuàng)新投融資焦點(diǎn)
Panel：2021 Investment and financing of biomedicine and health innovation in China Purchase focus
- 2021 上半年中國(guó)生物醫(yī)藥及健康領(lǐng)域并購(gòu)活動(dòng)及各市場(chǎng) IPO 情況說(shuō)明
2021 Description of M & A activities in the field of biomedicine and health in China and IPO in various markets in the first half of the year
- 疫情常態(tài)化與監(jiān)管政策中的投融資變化與未來(lái)分析
Investment and financing changes and future analysis in epidemic
normalization and regulatory policies  
- 中國(guó)正在如何逐步融入國(guó)際醫(yī)藥市場(chǎng)
How is China evolving in the international pharma market to access landscape
毛化，合伙人&董事總經(jīng)理，弗若斯特沙利文咨詢有限公司
袁寧，副首席商務(wù)官，復(fù)星醫(yī)藥
富天，昂闊醫(yī)藥首席商務(wù)官、聯(lián)合創(chuàng)始人，昂闊醫(yī)藥
巫薈，董事總經(jīng)理，泉?jiǎng)?chuàng)資本
李嘉，首席財(cái)務(wù)官，榮昌生物
Fred MAO,Partner&Managing Director,Frost & Sullivan
Ning YUAN,Deputy Chief Business Officer,Fosun Pharma
Andy Fu, PharmD, MBA,Co-Founder, Chief Business Officer,OnCusp Therapeutics 
Dr.Marietta WU,Managing Director,Quan Capital
Jason Li,CFO,RemeGen Ltd.
 
活動(dòng)免費(fèi)，名額有限。掃碼報(bào)名，先到先得！
 
聯(lián)系人CONTACT：李女士 Miss Li
電話TEL：18317040595
郵件EMAIL：1583832312@qq.com